MAX BioPharma is developing proprietary lipid based therapeutics for osteoporosis, localized bone growth (multiple applications) and pancreatic cancer.
Market:Osteoporosis: In the U.S., one in four women and one in four men over age 50 have osteoporosis. The global osteoporosis drug market was valued at $8.8 billion in 2015 and is expected to reach $15 billion by 2022. Localized Bone Formation: The global bone grafts and bone substitutes market is forecasted to reach $2.7 billion by 2020 with the US market accounting for 65.6% of this and growing at a CAGR of 11.7%. Oncology: Pancreatic cancer is the 7th most common cause of death from cancer globally, and 4th in the U.S. and Western Europe. The incidence of all types of pancreatic cancer are rising.
Technology:Based on its proprietary Oxysterol Therapeutics® platform technology, MAX BioPharma is developing bone anabolic agents for osteoporosis and localized bone growth, as well as anti-tumorigenic oxysterols to target multiple malignancies, including but not limited to pancreatic cancer. The company has developed a number of oxysterol small molecules that regulate normal physiology and disease and are excellent candidates for further therapeutic development.
- Small molecules with inexpensive synthesis
- Oral route of administration
- Superior efficacy
- Safer, more potent, and cost-effective
- Applicable to multiple indications
- Broad US and OUS intellectual property portfolio covering entire technology base and future areas of development with multiple awarded patents, filed applications, and composition of matter protection.
- Selected patents:
- Oxysterols and hedgehog signaling; 9,637,514
- Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins; 9,532,994
- Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling; 9,526,737
- Agents and methods for enhancing bone formation; 7,897,588
- MAX BioPharma Announces Key Updates on its Oxysterol Therapeutics™ Development Program, Intellectual Property Portfolio and Funding Initiatives | Cision PR Newswire
- MAX BioPharma Receives SBIR Phase 2 Grant from the National Institute of Aging | MAX BioPharma
- Comparison of a novel oxysterol molecule and rhBMP2 fusion rates in a rabbit posterolateral lumbar spine model | The Spine Journal
- Oxy133, a novel osteogenic agent, promotes bone regeneration in an intramembranous bone-healing model | Tissue Eng. Regen. Med.
- Inhibition of Pancreatic Cancer Cell-Induced Paracrine Hedgehog Signaling by Liver X Receptor Agonists and Oxy16, a Naturally Occurring Oxysterol | Journal of Cellular Biochemistry
Contact:Email: Farhad Parhami, firstname.lastname@example.org